{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:56Z","timestamp":1761975356704},"reference-count":114,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.pharmthera.2013.07.001","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T16:07:43Z","timestamp":1373299663000},"page":"213-222","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeted therapy of bronchitis in obstructive airway diseases"],"prefix":"10.1016","volume":"140","author":[{"given":"Angira","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Neighbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2013.07.001_bb0005","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.rmed.2010.02.018","article-title":"Increased serum IL-17 is an independent risk factor for severe asthma","volume":"104","author":"Agache","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1378\/chest.109.2.338","article-title":"BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics","volume":"109","author":"Aizawa","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2009.02.024","article-title":"T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma","volume":"123","author":"Al-Ramli","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.pharmthera.2013.07.001_bb0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2222.2011.03813.x","article-title":"A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma","volume":"42","author":"Barnes","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"2pt 1","key":"10.1016\/j.pharmthera.2013.07.001_bb0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/ajrccm.161.2.9903097","article-title":"Induced sputum cell counts in healthy adults","volume":"161","author":"Belda","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1155\/2006\/189127","article-title":"Predictors of loss of asthma control induced by corticosteroid withdrawal","volume":"13","author":"Belda","year":"2006","journal-title":"Can Respir J"},{"issue":"7","key":"10.1016\/j.pharmthera.2013.07.001_bb0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","article-title":"Evidence of a role of tumor necrosis factor alpha in refractory asthma","volume":"354","author":"Berry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1124\/pr.111.004622","article-title":"Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease","volume":"64","author":"Bezemer","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jaci.2007.10.028","article-title":"Targeting TNF-alpha: a novel therapeutic approach for asthma","volume":"121","author":"Brightling","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0570","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2004.032516","article-title":"Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease","volume":"60","author":"Brightling","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-7-135","article-title":"IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?","volume":"7","author":"Bullens","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0070","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaci.2012.10.013","article-title":"Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients","volume":"131","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0075","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/all.12003","article-title":"The single nucleotide polymorphism CRTh2 rs533116 is associated with allergic asthma and increased expression of CRTh2","volume":"67","author":"Campos Alberto","year":"2012","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00005792-199372030-00003","article-title":"The lung in inflammatory bowel disease","volume":"72","author":"Camus","year":"1993","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.pharmthera.2013.07.001_bb0085","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Res-5-0010 study group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pharmthera.2011.09.005","article-title":"Monoclonal antibodies for the treatment of asthma","volume":"132","author":"Catley","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/147323000603400202","article-title":"Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma","volume":"34","author":"Chlumsky","year":"2006","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0110","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.rmed.2007.05.010","article-title":"Changing pattern of sputum cell counts during successive exacerbations of airway disease","volume":"101","author":"D'silva","year":"2007","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2013.07.001_bb0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1155\/2008\/946735","article-title":"Cost analysis of monitoring asthma treatment using sputum cell counts","volume":"15","author":"D'silva","year":"2008","journal-title":"Can Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0125","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1378\/chest.09-3058","article-title":"Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD","volume":"138","author":"Doe","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.07.001_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1155\/2011\/920465","article-title":"Persistent sputum cellularity and neutrophils may predict bronchiectasis","volume":"18","author":"Drost","year":"2011","journal-title":"Can Respir J"},{"issue":"5","key":"10.1016\/j.pharmthera.2013.07.001_bb0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1155\/2007\/190618","article-title":"Sputum neutrophilia can mask eosinophilic bronchitis during exacerbations","volume":"14","author":"D'silva","year":"2007","journal-title":"Can Respir J"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1155\/2011\/430317","article-title":"Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice","volume":"18","author":"D'silva","year":"2011","journal-title":"Can Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0135","series-title":"Sputum Examination for Indices of Airway Inflammation: Laboratory Procedures","author":"Efthimiadis","year":"1997"},{"issue":"7","key":"10.1016\/j.pharmthera.2013.07.001_bb0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/rccm.200601-072OC","article-title":"The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma","volume":"174","author":"Erin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0145","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1164\/rccm.200708-1251OC","article-title":"Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses","volume":"177","author":"Gauvreau","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb9005","author":"Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA)","year":"2006"},{"issue":"9347","key":"10.1016\/j.pharmthera.2013.07.001_bb0150","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pharmthera.2013.07.001_bb0155","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.pharmthera.2013.07.001_bb0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1365-2222.1997.890900.x","article-title":"Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies","volume":"27","author":"Grootendorst","year":"1997","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0165","first-page":"203s","article-title":"Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD","author":"Gunawardena","year":"2010","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.pharmthera.2013.07.001_bb0170","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0175","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1164\/ajrccm.157.1.ed-19","article-title":"Inflammation and airway function in asthma: what you see is not necessarily what you get","volume":"157","author":"Haley","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2222.1992.tb03096.x","article-title":"The migration of eosinophils into the sputum of asthmatics: the role of adhesion molecules","volume":"22","author":"Hansel","year":"1992","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/ACI.0b013e328013e3c2","article-title":"Quantitative sputum cell counts as a marker of airway inflammation in clinical practice","volume":"7","author":"Hargreave","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5pt 2","key":"10.1016\/j.pharmthera.2013.07.001_bb0195","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1164\/ajrccm.160.supplement_1.14","article-title":"Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease","volume":"160","author":"Hargreave","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0200","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1365-2222.2009.03321.x","article-title":"The definition and diagnosis of asthma","volume":"39","author":"Hargreave","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0205","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1183\/09031936.06.00056106","article-title":"Asthma, COPD and bronchitis are just components of airway disease","volume":"28","author":"Hargreave","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0210","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jaci.2010.02.008","article-title":"Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes","volume":"125","author":"Hastie","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.pharmthera.2013.07.001_bb0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-7961-2-4","article-title":"Low-dose, long-term macrolide therapy in asthma: an overview","volume":"2","author":"Hatipoglu","year":"2004","journal-title":"Clin Mol Allergy"},{"issue":"8","key":"10.1016\/j.pharmthera.2013.07.001_bb0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/08958371003610966","article-title":"Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge","volume":"22","author":"Hernandez","year":"2010","journal-title":"Inhal Toxicol"},{"issue":"6","key":"10.1016\/j.pharmthera.2013.07.001_bb0230","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1183\/09031936.00063510","article-title":"Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial","volume":"37","author":"Holgate","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0235","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/09031936.00048509","article-title":"SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects","volume":"35","author":"Holz","year":"2010","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.pharmthera.2013.07.001_bb0240","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","article-title":"Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma","volume":"60","author":"Howarth","year":"2005","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.pharmthera.2013.07.001_bb0245","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1183\/09031936.96.09122441","article-title":"Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma","volume":"9","author":"in 't Veen","year":"1996","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.pharmthera.2013.07.001_bb0250","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1365-2222.1994.tb02725.x","article-title":"Non-invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic saline","volume":"24","author":"Iredale","year":"1994","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.07.001_bb0255","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201107-1317PP","article-title":"Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"185","author":"Jarjour","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0260","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1183\/09031936.06.00137704","article-title":"Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations","volume":"27","author":"Jayaram","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0265","series-title":"Methods in Molecular Medicine","first-page":"77","article-title":"Induced sputum: selection method","author":"Kelly","year":"2001"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11882-007-0032-0","article-title":"Are exhaled breath condensates useful in monitoring asthma?","volume":"7","author":"Ko","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0275","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1164\/rccm.2604007","article-title":"Asthma and chronic obstructive pulmonary disease exhibit common origins in any country!","volume":"174","author":"Kraft","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0280","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0091-6749(94)90252-6","article-title":"Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production","volume":"93","author":"Kroegel","year":"1994","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.07.001_bb0285","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rmed.2011.10.020","article-title":"AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide\/formoterol in patients with COPD","volume":"106","author":"Kuna","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1155\/1999\/858549","article-title":"Occupational neutrophilic asthma","volume":"6","author":"Leigh","year":"1999","journal-title":"Can Respir J"},{"issue":"5","key":"10.1016\/j.pharmthera.2013.07.001_bb0290","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0300","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood.V86.8.3181.3181","article-title":"Glucocorticoids inhibit apoptosis of human neutrophils","volume":"86","author":"Liles","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0305","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1155\/2012\/214129","article-title":"Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults: executive summary","volume":"19","author":"Lougheed","year":"2012","journal-title":"Can Respir J"},{"issue":"6","key":"10.1016\/j.pharmthera.2013.07.001_bb0310","first-page":"703","article-title":"Paranasal sinus disease and sputum eosinophilia in prednisone-dependent asthma","volume":"39","author":"Lui","year":"2010","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0315","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1164\/ajrccm.152.6.8520757","article-title":"Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage","volume":"152","author":"Maestrelli","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0320","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1378\/chest.126.3.926","article-title":"Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study","volume":"126","author":"Mahler","year":"2004","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.pharmthera.2013.07.001_bb0325","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently noneosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0330","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.105.097048","article-title":"A novel, selective, and orally available antagonist for CC chemokine receptor 3","volume":"317","author":"Morokata","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0340","series-title":"Eosinophils in Health and Disease","article-title":"Eosinophil targeted therapy of asthma","author":"Nair","year":"2012"},{"issue":"1","key":"10.1016\/j.pharmthera.2013.07.001_bb0370","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2013.05.007","article-title":"What is an \u201ceosinophilic phenotype\u201d of asthma?","volume":"132","author":"Nair","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.pharmthera.2013.07.001_bb0355","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0365","series-title":"Therapeutic Strategies in Asthma: Current Treatments","first-page":"155","article-title":"Airway diseases, inflammometry and individualized therapy","author":"Nair","year":"2007"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0335","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1378\/chest.10-0094","article-title":"Measuring bronchitis in airway diseases: clinical implementation and application. airway hyperresponsiveness in asthma: its measurement and clinical significance","volume":"138","author":"Nair","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pharmthera.2013.07.001_bb0345","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaci.2010.05.032","article-title":"Fraction of exhaled nitric oxide does not correlate with eosinophils in sputum in prednisone-dependent asthma","volume":"126","author":"Nair","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.pharmthera.2013.07.001_bb0360","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl. 51","key":"10.1016\/j.pharmthera.2013.07.001_bb0380","first-page":"209s","article-title":"Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers","volume":"30","author":"O'Connor","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0375","series-title":"A Single Dose of MEDI-528, a Monoclonal Antibody Against Interleukin-9, is Well Tolerated in Mild and Moderate Asthmatics in the Phase II Trial MI-CP-138","first-page":"478S","author":"O'Byrne","year":"2007"},{"issue":"Suppl. B","key":"10.1016\/j.pharmthera.2013.07.001_bb0385","doi-asserted-by":"crossref","first-page":"5B","DOI":"10.1155\/2007\/830570","article-title":"Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease \u2014 2007 update","volume":"14","author":"O'Donnell","year":"2007","journal-title":"Can Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0395","series-title":"Asthma: Epidemiology, Anti-inflammatory Therapy and Future Trends","first-page":"80","article-title":"Assessment of Airway Inflammation in Asthma using Non-invasive Methods","author":"Parameswaran","year":"2000"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0390","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1034\/j.1399-3003.2000.15.10.x","article-title":"Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma","volume":"15","author":"Parameswaran","year":"2000","journal-title":"Eur Respir J"},{"issue":"14","key":"10.1016\/j.pharmthera.2013.07.001_bb0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2466-11-14","article-title":"Safety profile and clinical activity of multiple subcutaneous doses ofMEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma","volume":"11","author":"Parker","year":"2011","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0405","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1155\/2008\/463762","article-title":"The clinical significance of exhaled nitric oxide in asthma","volume":"15","author":"Pendharkar","year":"2008","journal-title":"Can Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0410","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.200503-458OC","article-title":"Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial","volume":"172","author":"Pijnenburg","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2013.07.001_bb0430","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1164\/ajrccm.155.5.9154849","article-title":"Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment","volume":"155","author":"Pizzichini","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1183\/09031936.99.13101599","article-title":"Prednisone dependent asthma: inflammatory indices in induced sputum","volume":"13","author":"Pizzichini","year":"1999","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.07.001_bb0420","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0091-6749(97)70082-4","article-title":"Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood","author":"Pizzichini","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"2pt 1","key":"10.1016\/j.pharmthera.2013.07.001_bb0415","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1164\/ajrccm.154.2.8756799","article-title":"Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements","volume":"154","author":"Pizzichini","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.07.001_bb0435","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1164\/ajrccm.158.4.9712082","article-title":"Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"5 Pt 1","key":"10.1016\/j.pharmthera.2013.07.001_bb0425","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","article-title":"Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2013.07.001_bb0440","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1155\/1999\/434901","article-title":"Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteroid in patients without sputum eosinophilia","volume":"6","author":"Pizzichini","year":"1999","journal-title":"Can Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0450","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.iac.2007.09.004","article-title":"Urinary leukotriene E4","volume":"27","author":"Rabinovitch","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0455","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0460","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/ijbs.4874","article-title":"Role of IL-6 in asthma and other inflammatory pulmonary diseases","volume":"8","author":"Rincon","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0575","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.0903162","article-title":"IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation","volume":"184","author":"Roussel","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0465","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2010.12.1077","article-title":"Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy","volume":"127","author":"Saude","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0475","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1164\/rccm.200610-1427OC","article-title":"The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial","volume":"176","author":"Shaw","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.pharmthera.2013.07.001_bb9000","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI33559","article-title":"In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation","volume":"17","author":"Seshasayee","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmthera.2013.07.001_bb0485","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/thx.2006.061358","article-title":"Innate immune activation in neutrophilic asthma and bronchiectasis","volume":"62","author":"Simpson","year":"2007","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.pharmthera.2013.07.001_bb0480","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/rccm.200707-1134OC","article-title":"Clarithromycin targets neutrophilic airway inflammation in refractory asthma","volume":"177","author":"Simpson","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0490","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: a randomized controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0495","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1056\/NEJMoa043596","article-title":"Use of exhaled nitric oxide measurements to guide treatment in chronic asthma","volume":"352","author":"Smith","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0500","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.bbrc.2005.11.141","article-title":"In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031","volume":"339","author":"Suzuki","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.pharmthera.2013.07.001_bb0505","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/thx.2005.056093","article-title":"Exhaled nitric oxide measurements: clinical application and interpretation","volume":"61","author":"Taylor","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb6000","series-title":"Global strategy for the diagnosis, management and preven tion of chronic obstructive pulmonary disease","author":"The Global Initiative for Chronic Obstructive Lung Disease","year":"2011"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0510","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1164\/ajrccm.163.7.2010145","article-title":"PC20 adenosine 5-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine","volume":"163","author":"Van den berge","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0515","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1183\/09031936.00.16599700","article-title":"Success and safety of sputum induction in the clinical setting","volume":"16","author":"Vlachos-Mayer","year":"2000","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.pharmthera.2013.07.001_bb0520","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/15412555.2011.641803","article-title":"A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium","volume":"9","author":"Vogelmeier","year":"2012","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.pharmthera.2013.07.001_bb0525","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1183\/09031936.02.00226302","article-title":"Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma","volume":"19","author":"Wark","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0530","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1034\/j.1399-3003.2000.16f13.x","article-title":"Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis","volume":"16","author":"Wark","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0535","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1365-2222.2005.02306.x","article-title":"Involvement of distal airways in a chronic model of experimental asthma","volume":"35","author":"Wegmann","year":"2005","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.pharmthera.2013.07.001_bb0540","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"10.1016\/j.pharmthera.2013.07.001_bb0555","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0545","series-title":"Late Breaking Abstract: Inhaled Pitrakinra, an IL-4\/IL-13 Antagonist, Reduced Exacerbations in Patients with Eosinophilic Asthma","author":"Wenzel","year":"2010"},{"issue":"370","key":"10.1016\/j.pharmthera.2013.07.001_bb0550","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(07)61600-6","article-title":"Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies","volume":"20","author":"Wenzel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0560","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/15412550600651339","article-title":"Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease","volume":"3","author":"Wilson","year":"2006","journal-title":"COPD"},{"key":"10.1016\/j.pharmthera.2013.07.001_bb0565","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1046\/j.1365-2222.1999.00586.x","article-title":"Lack of relationship between eosinophil cationic protein and eosinophil protein X in nasal lavage and urine and the severity of childhood asthma in a 6-month follow-up study","volume":"29","author":"Wojnarowski","year":"1999","journal-title":"Clin Exp Allergy"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725813001460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T02:21:23Z","timestamp":1596075683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725813001460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0163725813001460"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.07.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy of bronchitis in obstructive airway diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2013.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}